Display options
Cite
Long LL, Podurgiel SJ, Haque AF, et al. Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat. Front Behav Neurosci. 2016;10:123doi: 10.3389/fnbeh.2016.00123.
Long, L. L., Podurgiel, S. J., Haque, A. F., Errante, E. L., Chrobak, J. J., & Salamone, J. D. (2016). Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat. Frontiers in behavioral neuroscience, 10123. https://doi.org/10.3389/fnbeh.2016.00123
Long, Lauren L, et al. "Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat." Frontiers in behavioral neuroscience vol. 10 (2016): 123. doi: https://doi.org/10.3389/fnbeh.2016.00123
Long LL, Podurgiel SJ, Haque AF, Errante EL, Chrobak JJ, Salamone JD. Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat. Front Behav Neurosci. 2016 Jun 17;10:123. doi: 10.3389/fnbeh.2016.00123. eCollection 2016. PMID: 27378874; PMCID: PMC4911403.
Copy Download .nbib Format: NLM
Share it on

Front Behav Neurosci. 2016 Jun 17;10:123. doi: 10.3389/fnbeh.2016.00123. eCollection 2016.

Subthalamic and Cortical Local Field Potentials Associated with Pilocarpine-Induced Oral Tremor in the Rat.

Frontiers in behavioral neuroscience

Lauren L Long, Samantha J Podurgiel, Aileen F Haque, Emily L Errante, James J Chrobak, John D Salamone

Affiliations

  1. Department of Psychological Sciences, University of Connecticut Storrs, CT, USA.

PMID: 27378874 PMCID: PMC4911403 DOI: 10.3389/fnbeh.2016.00123

Abstract

Tremulous jaw movements (TJMs) are rapid vertical deflections of the lower jaw that resemble chewing but are not directed at any particular stimulus. In rodents, TJMs are induced by neurochemical conditions that parallel those seen in human Parkinsonism, including neurotoxic or pharmacological depletion of striatal dopamine (DA), DA antagonism, and cholinomimetic administration. Moreover, TJMs in rodents can be attenuated by antiparkinsonian agents, including levodopa (L-DOPA), DA agonists, muscarinic antagonists, and adenosine A2A antagonists. In human Parkinsonian patients, exaggerated physiological synchrony is seen in the beta frequency band in various parts of the cortical/basal ganglia/thalamic circuitry, and activity in the tremor frequency range (3-7 Hz) also has been recorded. The present studies were undertaken to determine if tremor-related local field potential (LFP) activity could be recorded from motor cortex (M1) or subthalamic nucleus (STN) during the TJMs induced by the muscarinic agonist pilocarpine, which is a well-known tremorogenic agent. Pilocarpine induced a robust TJM response that was marked by rhythmic electromyographic (EMG) activity in the temporalis muscle. Compared to periods with no tremor activity, TJM epochs were characterized by increased LFP activity in the tremor frequency range in both neocortex and STN. Tremor activity was not associated with increased synchrony in the beta frequency band. These studies identified tremor-related LFP activity in parts of the cortical/basal ganglia circuitry that are involved in the pathophysiology of Parkinsonism. This research may ultimately lead to identification of the oscillatory neural mechanisms involved in the generation of tremulous activity, and promote development of novel treatments for tremor disorders.

Keywords: LFP; Parkinsonism; acetylcholine; motor cortex; muscarinic; tremulous jaw movements

References

  1. Eur Neuropsychopharmacol. 2013 Aug;23(8):972-7 - PubMed
  2. Exp Neurol. 2004 Oct;189(2):369-79 - PubMed
  3. Eur J Neurosci. 2006 Apr;23(7):1956-60 - PubMed
  4. J Neurol Neurosurg Psychiatry. 2000 May;68(5):595-600 - PubMed
  5. Clin Neurophysiol. 2005 Nov;116(11):2510-9 - PubMed
  6. Behav Brain Res. 2005 Jan 30;156(2):173-9 - PubMed
  7. J Neurosci. 2000 Oct 15;20(20):7766-75 - PubMed
  8. J Neurosci. 2001 Feb 1;21(3):1033-8 - PubMed
  9. Prog Neurobiol. 1998 Dec;56(6):591-611 - PubMed
  10. Eur J Neurosci. 2013 Jul;38(1):2183-91 - PubMed
  11. Prog Brain Res. 2011;194:105-16 - PubMed
  12. J Neurosci. 2008 Apr 30;28(18):4795-806 - PubMed
  13. Exp Neurol. 2011 Sep;231(1):82-90 - PubMed
  14. Br Med Bull. 1973 May;29(2):172-8 - PubMed
  15. Eur J Neurosci. 2005 Mar;21(5):1413-22 - PubMed
  16. Brain. 2003 Jan;126(Pt 1):199-212 - PubMed
  17. Parkinsonism Relat Disord. 2009 Jan;15(1):30-5 - PubMed
  18. Brain. 2013 Dec;136(Pt 12):3659-70 - PubMed
  19. Neuroscience. 2009 Sep 29;163(1):97-108 - PubMed
  20. Mov Disord. 2006 Oct;21(10):1663-6 - PubMed
  21. Neuropsychopharmacology. 2015 Aug;40(9):2240-7 - PubMed
  22. Neurologia. 2014 Sep;29(7):416-22 - PubMed
  23. Brain. 2002 Jun;125(Pt 6):1196-209 - PubMed
  24. Arch Neurol. 1967 Aug;17(2):124-36 - PubMed
  25. Pharmacol Biochem Behav. 1997 Feb;56(2):273-9 - PubMed
  26. J Neurol Sci. 2006 Oct 25;248(1-2):48-52 - PubMed
  27. Intern Med. 2000 Oct;39(10):863 - PubMed
  28. Adv Neurol. 1975;9:165-75 - PubMed
  29. J Psychosoc Nurs Ment Health Serv. 1994 Mar;32(3):37-9 - PubMed
  30. Pharmacol Biochem Behav. 2015 Apr;131:1-5 - PubMed
  31. Parkinsonism Relat Disord. 2008;14 Suppl 2:S130-4 - PubMed
  32. Neuroscience. 2013 Oct 10;250:507-19 - PubMed
  33. Eur J Pharmacol. 1999 Jan 1;364(1):7-11 - PubMed
  34. Int Psychogeriatr. 1998 Sep;10(3):229-38 - PubMed
  35. Neuroscience. 2005;133(3):831-40 - PubMed
  36. Prog Brain Res. 2010;183:235-58 - PubMed
  37. Clin Neurophysiol. 2002 Nov;113(11):1667-72 - PubMed
  38. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593 - PubMed
  39. Eur J Neurosci. 2009 Feb;29(3):599-612 - PubMed
  40. N Engl J Med. 2006 Aug 31;355(9):896-908 - PubMed
  41. Exp Neurol. 2004 Sep;189(1):182-8 - PubMed
  42. Pharmacol Biochem Behav. 2013 Apr;105:105-11 - PubMed
  43. Eur J Pharmacol. 1997 Mar 19;322(2-3):137-45 - PubMed
  44. J Neurosci. 1991 Dec;11(12):3822-9 - PubMed
  45. Pharmacol Biochem Behav. 2012 Jan;100(3):498-505 - PubMed
  46. Physiol Behav. 1998 May;64(2):153-8 - PubMed
  47. J Neurosci Methods. 2005 Jun 30;145(1-2):151-8 - PubMed
  48. Front Biosci. 2008 May 01;13:3594-605 - PubMed
  49. Exp Neurol. 2005 Jul;194(1):212-20 - PubMed
  50. Front Syst Neurosci. 2011 Jul 04;5:49 - PubMed
  51. Trends Neurosci. 2007 Jul;30(7):357-64 - PubMed
  52. Pharmacol Biochem Behav. 2012 Oct;102(4):477-87 - PubMed
  53. Mov Disord. 2010 Apr 15;25(5):578-86 - PubMed
  54. Clin Neuropharmacol. 1992 Aug;15(4):322-5 - PubMed
  55. Int J Geriatr Psychiatry. 2003 Oct;18(10):937-41 - PubMed
  56. Curr Opin Neurol. 2013 Dec;26(6):662-70 - PubMed
  57. J Neurophysiol. 1994 Aug;72(2):507-20 - PubMed
  58. Neuroimage Clin. 2013 Aug 08;3:261-70 - PubMed
  59. J Clin Psychopharmacol. 1983 Oct;3(5):288-302 - PubMed
  60. Mov Disord. 2003 Apr;18(4):357-63 - PubMed
  61. Mov Disord. 1995 Sep;10(5):672-4 - PubMed
  62. J Neurosci. 2004 Oct 20;24(42):9240-3 - PubMed
  63. Parkinsonism Relat Disord. 2008 Nov;14(7):584-5 - PubMed
  64. Pharmacol Biochem Behav. 2010 Feb;94(4):561-9 - PubMed
  65. Behav Brain Res. 2015 Jul 15;288:103-6 - PubMed

Publication Types